News for HROW Stock

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension) Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025 Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance Harrow Launches VEVYE® Access for All Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE® Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025 Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients Harrow Appoints Amir H. Shojaei as Chief Scientific Officer OSRX, Inc. Responds to Jury Verdict in Trademark Infringement Case Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc. Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery Harrow Announces Participation in Upcoming Investor Conferences Harrow Announces Third Quarter 2024 Financial Results Harrow Launches Access and Affordability Program with Price Reductions for Branded Products Harrow Announces Market Access Wins for VEVYE® Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare Products Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024 Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery Harrow Relaunches TRIESENCE® Harrow Announces Nashville Expansion Harrow to Present at Three Investor Conferences in September in New York Harrow Announces Second Quarter 2024 Financial Results Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024 Harrow to Attend 2024 ASRS Annual Meeting Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products Harrow Provides TRIESENCE® Relaunch Update Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study Harrow to Present at Two Investor Conferences in May Harrow Announces First Quarter 2024 Financial Results Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024 Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing Harrow Announces Fourth Quarter and Year-End 2023 Financial Results Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024 Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products Harrow Announces New Appointments to its Board of Directors Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease Melt Pharmaceuticals Provides Corporate Update Harrow Partners with Leading Healthcare Market Access Technology Platforms Harrow Completes Transfer of the TRIESENCE® New Drug Application Harrow to Present at Two Investor Conferences in November Harrow Announces Third Quarter 2023 Financial Results Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023 Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S. Harrow Health, Inc. Changes Corporate Name to Harrow, Inc. Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation Harrow Announces Second Quarter 2023 Financial Results Harrow Launches VIGAMOX® in the U.S. Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023 Harrow Prices $60 Million Public Offering of Common Stock Harrow Acquires Santen’s Branded Ophthalmic Portfolio Santen Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North America Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance Harrow Announces Proposed Public Offering of Common Stock Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023 Harrow Announces First Quarter 2023 Financial Results Harrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting Harrow Launches ILEVRO®, NEVANAC®, and MAXIDEX® in the U.S. Harrow to Announce First Quarter 2023 Financial Results on May 11, 2023 B. Riley Leads Financing to Support Harrow Health Acquisition Harrow Announces New $100 Million Secured Credit Facility with Oaktree Harrow Announces Fourth Quarter and Year-End 2022 Financial Results Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance Harrow to Announce Fourth Quarter 2022 Financial Results on March 23, 2023 Harrow Launches Next-Generation Compounded Atropine Formulations Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023 Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products Harrow Announces Availability of Fortisite™ Formulations for In-Office Use Melt Pharmaceuticals’ MELT-300 (Midazolam 3mg and Ketamine 50mg Sublingual Tablet) Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Study Harrow Secures Capital to Close Recently Announced Acquisition Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and “BB” Rating from Egan-Jones Harrow Prices $25 Million Offering Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® Harrow and iOR Partners Expand National Product Supply Agreement Harrow Announces Third Quarter 2022 Financial Results Harrow Launches Atropine.com Harrow to Announce Third Quarter 2022 Financial Results on November 14, 2022 Melt Pharmaceuticals Announces Dosing of Last Patient in Phase 2 Pivotal Efficacy and Safety Study for MELT-300 Harrow Sells Non-Ophthalmic Compounding Business ImprimisRx Launches Fortisite™ (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Harrow Health to Participate in H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference Harrow Health Announces Second Quarter 2022 Financial Results Harrow Health to Announce Second Quarter 2022 Financial Results on August 9, 2022 Harrow Health Announces Launch of IOPIDINE® 1% and MAXITROL® in the United States Harrow Health Announces First Quarter 2022 Financial Results Melt Pharmaceuticals Announces MELT-210 Top-Line Results of Phase 1 Pharmacokinetics (PK) Study for Procedural Sedation Harrow Health to Participate in B. Riley Securities’ Annual Neuro & Ophthalmology Investor Conference Harrow Health to Announce First Quarter 2022 Financial Results on May 5, 2022 Harrow Health Announces Appointments to Its Board of Directors Harrow Health Announces Fourth Quarter and Year-End 2021 Financial Results Melt Pharmaceuticals Names Experienced Executive Brad Osborne as Chief Financial Officer Harrow Health to Announce Fourth Quarter and Year-End 2021 Financial Results on March 10, 2022 Harrow Health Announces FDA Acceptance of New Drug Application for AMP-100 Harrow Health to Present at Aegis Virtual Conference Harrow Health Publishes Corporate Transparency Report Harrow Health to Participate in H.C. Wainwright BioConnect Conference Melt Pharmaceuticals Submits INDs for MELT‑210 and MELT-400 to FDA Harrow Health Acquires U.S. Commercial Rights to Four Branded Eye Drops Harrow Health Added to the Nasdaq Biotechnology Index Harrow Health Announces Third Quarter 2021 Financial Results Harrow Health to Announce Third Quarter 2021 Financial Results on November 9, 2021 Harrow Health Provides $13.5 Million Senior Secured Loan to Melt Pharmaceuticals Harrow Health Acquires Ophthalmic Surgical Drug Candidate From Wakamoto Pharmaceutical Co., Ltd. Harrow Health to Participate in Two Upcoming Virtual Investor Conferences Harrow Health Announces Second Quarter 2021 Financial Results Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica Harrow Health to Announce Second Quarter 2021 Financial Results on August 10, 2021 NovaBay Pharmaceuticals Partners with Harrow Health’s ImprimisRx® to Promote Prescription Avenova Harrow Health Granted Two Patents for Novel Surgical Dilation Formulation Harrow Health Announces Closing of $20 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026 Harrow Health Announces Pricing of $17.5 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026 Harrow Health Announces Offering of $17.5 Million of 8.625% Senior Notes Due 2026 and “BB” Rating from Egan-Jones Harrow Health Launches New Corporate and Investor Website Leading Peer-Reviewed Ophthalmic Journal Publishes Study on ImprimisRx’s Proprietary Klarity-C® Drops Harrow Health Announces Record First Quarter 2021 Financial Results Harrow Health Raises Approximately $11 Million in Sale of Series B Preferred Stock Harrow Health Announces Full Exercise and Closing of Option to Purchase Additional Senior Notes Harrow Health to Announce First Quarter 2021 Financial Results on May 11, 2021 Harrow Health Announces Closing of $50 Million Offering of Senior Notes Due 2026 Harrow Health Announces Pricing of $50 Million Offering of Senior Notes Due 2026 Harrow Health Announces Offering of $25 Million Senior Notes Due 2026 and “BB” Rating from Egan-Jones Harrow Health Announces Preliminary First Quarter 2021 Financial Results Harrow Health Announces Fourth Quarter and Year-End 2020 Financial Results Harrow Health to Participate in H.C. Wainwright Global Life Sciences Conference Harrow Health to Announce Fourth Quarter and Year-End 2020 Financial Results on March 8, 2021 Melt Pharmaceuticals Completes Phase 1 Study for Sublingual, Non-Opioid Pain and Sedation Drug Candidate Study on Patented Non-Opioid MKO Melt® Reported in Leading Peer-Reviewed Anesthesia Journal Harrow Health Announces Participation at the Piper Sandler 32nd Annual Healthcare Conference Harrow Health Publishes Third Quarter 2020 Letter to Stockholders Harrow Health to Announce Third Quarter 2020 Financial Results on November 9, 2020 Harrow Health to Attend Lake Street’s Virtual 4th Annual (BIG4) Conference September 17, 2020 Harrow Health Publishes Second Quarter 2020 Letter to Stockholders Harrow Health to Announce Second Quarter 2020 Financial Results on August 10, 2020 ImprimisRx’s Patented Klarity-C® 0.1% Cyclosporine Preservative-Free Formulation May Now Be Prescribed By Florida’s 2,000 Optometrists Harrow Health to Announce First Quarter 2020 Financial Results on May 11, 2020 Leading Peer-Reviewed Journal Publishes Clinical Study on ImprimisRx’s Combination Prescription Eyedrops Harrow Health Publishes First Quarter 2020 Letter to Stockholders